NVAX Novavax Inc

Price (delayed)

$7.435

Market cap

$1.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$1.29B

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 32
Relative Valuation: Rel. Valuation: 21
Relative Profitability: Rel. Profitability: 22

Novavax, Inc. tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The ...

Highlights
NVAX's quick ratio is up by 29% since the previous quarter and by 28% year-on-year
Novavax's net income has plunged by 120% from the previous quarter and by 118% YoY
Novavax's EPS has shrunk by 120% QoQ and by 118% YoY

Key stats

What are the main financial stats of NVAX

NVAX stock price

How has the Novavax stock price performed over time
Intraday
1.57%
1 week
-0.73%
1 month
-23.67%
1 year
13.34%
YTD
10.64%
QTD
-21.07%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$596.34M
Gross profit
$506.72M
Operating income
-$78.15M
Net income
-$87.84M
Gross margin
85%
Net margin
-14.7%
The operating margin has dropped by 140% year-on-year and by 133% since the previous quarter
Novavax's net margin has shrunk by 139% YoY and by 138% QoQ
Novavax's net income has plunged by 120% from the previous quarter and by 118% YoY
Novavax's operating income has plunged by 119% YoY and by 117% from the previous quarter

Price vs fundamentals

How does NVAX's price correlate with its fundamentals

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
2.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.16
Novavax's EPS has shrunk by 120% QoQ and by 118% YoY
Novavax's equity has shrunk by 91% YoY and by 13% QoQ
The revenue has plunged by 52% YoY and by 47% from the previous quarter
NVAX's P/S is 43% above its last 4 quarters average of 1.4 but 17% below its 5-year quarterly average of 2.4

Efficiency

How efficient is Novavax business performance
Novavax's return on sales has shrunk by 127% YoY and by 126% QoQ
NVAX's return on assets has dropped by 125% year-on-year and by 121% since the previous quarter
The ROIC has plunged by 114% from the previous quarter and by 104% YoY

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 12% lower than its total liabilities
NVAX's quick ratio is up by 29% since the previous quarter and by 28% year-on-year
The current ratio has increased by 20% year-on-year and by 16% since the previous quarter
Novavax's equity has shrunk by 91% YoY and by 13% QoQ
NVAX's debt to equity is up by 32% year-on-year but it is down by 4.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.